VX-166
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:510228
CAS#:800408-39-3
Description:VX-166 is a broad caspase inhibitor, which can be used as a novel potential treatment for sepsis. VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Price and Availability
VX-166 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 510228Name: VX-166CAS#: 800408-39-3Chemical Formula: C22H21F4N3O8Exact Mass: 531.12648Molecular Weight: 531.41Elemental Analysis: C, 49.72; H, 3.98; F, 14.30; N, 7.91; O, 24.09
Synonym:VX166, VX 166, VX-166
IUPAC/Chemical Name:(S)-3-((S)-2-(3-((methoxycarbonyl)amino)-2-oxopyridin-1(2H)-yl)butanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
InChi Key:WQNDPVUOABHOHK-KBPBESRZSA-N
InChi Code:InChI=1S/C22H21F4N3O8/c1-3-14(29-6-4-5-12(21(29)34)28-22(35)36-2)20(33)27-13(8-16(31)32)15(30)9-37-19-17(25)10(23)7-11(24)18(19)26/h4-7,13-14H,3,8-9H2,1-2H3,(H,27,33)(H,28,35)(H,31,32)/t13-,14-/m0/s1
SMILES Code:O=C(O)C[C@H](NC([C@@H](N1C=CC=C(NC(OC)=O)C1=O)CC)=O)C(COC2=C(F)C(F)=CC(F)=C2F)=O
Technical Data
References
1: Collins JL, Peng X, Lee R, Witriol A, Pierre Z,Sciuto AM. Determination of LCt(50)s in anesthetized rats exposed toaerosolized nerve agents. Toxicol Mech Methods. 2013 Feb;23(2):127-33.doi: 10.3109/15376516.2012.730560. Epub 2012 Oct 19. PubMed PMID:22978758.
2: Anstee QM, Concas D, Kudo H, Levene A, Pollard J, Charlton P, ThomasHC, Thursz MR, Goldin RD. Impact of pan-caspase inhibition in animalmodels of established steatosis and non-alcoholic steatohepatitis. JHepatol. 2010 Sep;53(3):542-50. doi: 10.1016/j.jhep.2010.03.016. Epub2010 May 26. PubMed PMID: 20557969.
3: Weber P, Wang P, Maddens S, Wang PSh, Wu R, Miksa M, Dong W,Mortimore M, Golec JM, Charlton P. VX-166: a novel potent small moleculecaspase inhibitor as a potential therapy for sepsis. Crit Care.2009;13(5):R146. doi: 10.1186/cc8041. Epub 2009 Sep 9. PubMed PMID:19740426; PubMed Central PMCID: PMC2784364.
4: Witek RP, Stone WC, Karaca FG, Syn WK, Pereira TA, Agboola KM,Omenetti A, Jung Y, Teaberry V, Choi SS, Guy CD, Pollard J, Charlton P,Diehl AM. Pan-caspase inhibitor VX-166 reduces fibrosis in an animalmodel of nonalcoholic steatohepatitis. Hepatology. 2009Nov;50(5):1421-30. doi: 10.1002/hep.23167. PubMed PMID: 19676126.
5: Hilmas CJ, Poole MJ, Finneran K, Clark MG, Williams PT. Galantamineis a novel post-exposure therapeutic against lethal VX challenge.Toxicol Appl Pharmacol. 2009 Oct 15;240(2):166-73. doi:10.1016/j.taap.2009.07.029. Epub 2009 Jul 30. PubMed PMID: 19647007.
6: Sakurada K, Ikegaya H, Ohta H, Akutsu T, Takatori T. Hydrolysis of anacetylthiocholine by pralidoxime iodide (2-PAM). Toxicol Lett. 2006 Oct25;166(3):255-60. Epub 2006 Aug 12. PubMed PMID: 16971069.
7: Haberham ZL, van den Brom WE, Venker-van Haagen AJ, de Groot HN,Baumans V, Hellebrekers LJ. The rat vertex-middle latencyauditory-evoked potential as indicator of anaesthetic depth: acomparison with evoked-reflex testing. Brain Res. 2000 Aug11;873(2):287-90. PubMed PMID: 10930556.
8: Bosković B. The influence of 2-/o-cresyl/-4 H-1 : 3 :2-benzodioxa-phosphorin-2-oxide (CBDP) on organophosphate poisoning andits therapy. Arch Toxicol. 1979 Jul 11;42(3):207-16. PubMed PMID:475595.
MedKoo,由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区(ResearchTrianglePark,简称RTP),是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司,该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。
中文名MedKoo中 文美帝药库医药科技公司创立于2008年总部位于美国东海岸
MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务。 MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务和分子有竞争力的价格。MedKoo是您可靠的合作伙伴采购药物发现和药物分子。 MedKoo是世界的抗癌化学试剂和激酶抑制剂供应商之一。我们制造,销售和分销用于肿瘤学研究的高质量抗癌小分子试剂。我们的使命是建立世界上全面的抗癌小分子集合。我们还为制药行业,医学研究组织和学术机构提供高质量的研究服务。我们致力于以具有竞争力的价格提供服务和分子。MedKoo是您可靠的药物发现和药物分子采购合作伙伴。 CRISPR-Cas9是近年兴起的用于靶向基因组特定位置,进行DNA修饰的重要工具。研究发现CRISPR是细菌为了应对病毒的攻击而演化而来的获得性免疫防御机制。具体来说,在CRISPR和Cas9的作用下,经由小RNA分子的引导,靶向并沉默入侵者遗传物质核酸的关键部分。在该系统中,crRNA(CRISPR-derivedRNA)与tracrRNA(trans-activatingRNA)结合形成的复合物能特异性识别靶基因序列,并引导Cas9核酸内切酶在靶定位点剪切双链DNA,随后,细胞的非同源末端连接修复机制(NHEJ)重新连接断裂处的基因组DNA,并引入插入或缺失突变。另外也可以提供一个外源双链供体DNA(Donor)通过同源重组(HR)整合进断裂处的基因组,从而达到对基因组DNA进行修饰的目的。
目前,CRISPR-Cas9系统的高效基因组编辑功能已被应用于多种生物,包括小鼠、大鼠、斑马鱼、秀丽隐杆线虫,也包含多种细菌和植物,甚至在人体上也有应用。
ebiomall.com
暂无品牌问答